Table 3. Clinical course of UM in DTC patients (n = 19).
| Diagnostic method for UM | |
| Pathology | 10 (52.6) |
| FNA | 4 (21.1) |
| Biopsy | 5 (31.3) |
| Surgical specimen | 1 (6.3) |
| Imaging studies | 9 (47.4) |
| RAI uptake ± CT/MRI | 2 (10.5) |
| 18-FDG uptake ± CT/MRI | 7 (36.8) |
| First-line therapy for UM | |
| Observation | 4 (21.1) |
| Local treatment | 5 (31.3) |
| Surgery (including excision) | 3 (15.8) |
| RFA | 2 (10.5) |
| Systemic treatment | 10 (52.6) |
| TKI therapy | 5 (31.3) |
| RAI ablation therapy | 4 (21.1) |
| Systemic chemotherapy | 1 (5.3) |
| Mortality rate | 6 (31.6) |
| Cancer-related mortality | 6 (31.6) |
| Treatment-related mortality | 0 (0.0) |
| Median follow-up months from UM diagnosis (IQR) | 20.0 (11.0–55.0) |
UM: unusual metastasis; RAI: radioactive iodine; FDG: fluoro-deoxy-glucose; RFA: radiofrequency ablation; TKI: tyrosine kinase inhibitor; IQR: interquartile range